Sprechstunden/ Spezialsprechstunden am MGZ
Boosting care and knowledge about hereditary cancer: European Reference Network on Genetic Tumour Risk Syndromes
Approximately 27-36 million patients in Europe have one of the ~ 5.000-8.000 known rare diseases. These patients often do not receive the care they need or they have a substantial delay from diagnosis to treatment. In March 2017, twenty-four European Reference Networks (ERNs) were launched with the aim to improve the care for these patients through cross border healthcare, in a way that the medical knowledge and expertise travels across the borders, rather than the patients. It is expected that through the ERNs, European patients with a rare disease get access to expert care more often and more quickly, and that research and guideline development will be accelerated resulting in improved diagnostics and therapies. The ERN on Genetic Tumour Risk Syndromes (ERN GENTURIS) aims to improve the identification, genetic diagnostics, prevention of cancer, and treatment of European patients with a genetic predisposition for cancer. The ERN GENTURIS focuses on syndromes such as hereditary breast cancer, hereditary colorectal cancer and polyposis, neurofibromatosis and more rare syndromes e.g. PTEN Hamartoma Tumour Syndrome, Li Fraumeni Syndrome and hereditary diffuse gastric cancer.
Fam Cancer. 2019;18(2):281-284.
Es wurden keine Änderungen des Artikels vorgenommen.
Die Publikation steht Ihnen im Folgenden zum Download bereit:
MGZBoosting care and knowledge about hereditary cancer_ European Reference Network on Genetic Tumour Risk Syndromes.pdf